ReviewHepatology international2019
Hepatocellular carcinoma and non-alcoholic fatty liver disease.
Review in Hepatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessment of Prognostic Value of Aspartate Aminotransferase-to-Platelet Ratio Index in Patients With Hepatocellular Carcinoma: Meta-Analysis of 28 Cohort Studies.Frontiers in medicine · 2021Pooled it
- ADCK1 Regulates Mitochondrial Bioenergetics in Hepatocellular Carcinoma In Vitro.International journal of molecular sciences · 2026Article
- Single-cell transcriptomic profile unveils distinct immune ecosystems in alcohol- and nonalcohol-associated hepatocellular carcinoma.Frontiers in immunology · 2026Article
- The antineoplastic effects of nuciferine on hepatocellular carcinoma are associated with suppression of the HER2-AKT/ERK1/2 signaling pathway.Discover oncology · 2025Article
- Revealing the prognostic potential of natural killer cell-related genes in hepatocellular carcinoma: the key role of NRAS.Discover oncology · 2025Article
- Preventive role of Pastinaca sativa in mitigating metabolic dysfunction-associated steatotic liver disease via modulation of metabolic endotoxemia.NPJ science of food · 2025Article
- Exercise-Induced Increase in Serum Irisin Levels is Associated with Antioxidant Effects of Silymarin in Dexamethasone- Induced NAFLD.International journal of preventive medicine · 2025Article
- Effects and Mechanism ofCombinatorial chemistry & high throughput screening · 2025Article
- Advances in the Pathogenesis of Metabolic Liver Disease-Related Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Review
- Hepatic vagotomy blunts liver regeneration after hepatectomy by downregulating the expression of interleukin-22.World journal of gastrointestinal surgery · 2023Article
- Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS.The Journal of clinical endocrinology and metabolism · 2023Article
- Beneficial Effects of Viable and Heat-InactivatedAntioxidants (Basel, Switzerland) · 2023Article
- Article
- Pathogenesis of NAFLD-Related Hepatocellular Carcinoma: An Up-to-Date Review.Journal of hepatocellular carcinoma · 2023Review
- The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019.JMIR public health and surveillance · 2022Article
- Estrogen Deficiency Aggravates Fluoride-Induced Liver Damage and Lipid Metabolism Disorder in Rats.Biological trace element research · 2022Article
- Differences Between Sorafenib and Lenvatinib Treatment from Genetic and Clinical Perspectives for Patients with Hepatocellular Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Structure based innovative approach to analyze aptaprobe-GPC3 complexes in hepatocellular carcinoma.Journal of nanobiotechnology · 2022Article
- Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges.Journal of hepatocellular carcinoma · 2022Review
- Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.Cancer management and research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder worldwide, affecting 25.2% of the general population. In fact, NAFLD is among the most common etiologies for hepatocellular carcinoma (HCC). The burden of NAFLD is primarily driven by the epidemic of obesity and type 2 diabetes which are expected to worsen throughout the world. In this context, the burden of NAFLD and associated HCC and cirrhosis are also expected to increase. Despite its growing disease burden, diagnostic tools and treatment modalities remain very limited. This conundrum of increasing prevalence and limited treatment options will be reflected as increasing number of NAFLD-related cirrhosis and HCC cases. This article reviews the most updated information about NAFLD-related HCC and provides some insight into strategies that must be considered to reduce its potential disease burden.
Indexed as
Identifiers
31701393What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.